Department of Global Health and Bio-Medical Sciences, School of Life Sciences and Bio-Engineering, Nelson Mandela African Institution of Science and Technology (NM-AIST), P.O. Box 447, Arusha, Tanzania.
Department of Bio-Medical Sciences, School of Medicine and Dentistry, College of Health Sciences, University of Dodoma, P.O. Box 259, Dodoma, Tanzania.
Biomed Res Int. 2017;2017:7035025. doi: 10.1155/2017/7035025. Epub 2017 Sep 28.
Administering more than one treatment may increase Praziquantel cure and egg reduction rates, thereby hastening achievement of schistosomiasis transmission control. A total of 431 -infected schoolchildren were randomized to receive either a single or repeated 40 mg/kg Praziquantel dose. Heights, weights, and haemoglobin levels were determined using a stadiometer, weighing scale, and HemoCue, respectively. At 8 weeks, cure rate was higher on repeated dose (93.10%) compared to single dose (68.68%) ( < 0.001). The egg reduction rate was higher on repeated dose (97.54%) compared to single dose (87.27%) ( = 0.0062). Geometric mean egg intensity was lower among those on repeated dose (1.30 epg) compared to single dose (3.18 epg) ( = 0.036) but not at 5 ( > 0.05) and 8 ( > 0.05) months with no difference in reinfection rate. No difference in the prevalence of stunting was observed between the two treatment regimens ( > 0.05) at 8 months, but there was an increase in the prevalence of wasting among those on repeated dose ( < 0.001). There was an increase in the mean haemoglobin levels at 8 months with no difference between the two arms ( > 0.05). To achieve reduction of transmission intensity and disease control in highly endemic areas, repeated treatments alone may not be sufficient. This trial was registered with PACTR201601001416338.
给予多种治疗可能会提高吡喹酮的治愈率和虫卵减少率,从而加速实现血吸虫病传播控制。共有 431 名受感染的学龄儿童被随机分为接受单次或重复 40mg/kg 吡喹酮剂量的治疗。使用身高计、体重秤和 HemoCue 分别测量身高、体重和血红蛋白水平。在 8 周时,重复剂量的治愈率(93.10%)高于单次剂量(68.68%)(<0.001)。重复剂量的虫卵减少率(97.54%)高于单次剂量(87.27%)(=0.0062)。重复剂量组的几何平均虫卵强度(1.30epg)低于单次剂量组(3.18epg)(=0.036),但在 5 个月(>0.05)和 8 个月(>0.05)时无差异。在 8 个月时,两种治疗方案的发育迟缓患病率无差异(>0.05),但重复剂量组的消瘦患病率增加(<0.001)。8 个月时血红蛋白水平均值增加,两组之间无差异(>0.05)。为了降低高度流行地区的传播强度和疾病控制,单独重复治疗可能还不够。该试验已在 PACTR201601001416338 注册。